Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BG-C0979 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on BG-C0979, a putative antibody-drug conjugate (ADC) targeting ADAM9 (May 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BG-C0979 | BGC0979|BG C0979 | Limited information is currently available on BG-C0979, a putative antibody-drug conjugate (ADC) targeting ADAM9 (May 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07414836 | Phase I | BG-C0979 BG-C0979 + Tislelizumab | A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors | Recruiting | USA | AUS | 0 |